CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Seoul, Korea, Republic of and 173 other locations
(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...
Phase 3
Seoul, Korea, Republic of and 108 other locations
of dose-limiting toxicity (DLT) in newly diagnosed Acute Myeloid Leukemia (AML) subjects. Phase 1 part will also evaluate safety and tolerab...
Phase 1, Phase 2
Seoul, Korea, Republic of and 54 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in a...
Phase 1
Seoul, Seoul Teugbyeolsi, Korea, Republic of and 20 other locations
with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...
Phase 3
Seoul, Korea, Republic of and 108 other locations
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior m...
Phase 3
Seoul, Korea, Republic of and 222 other locations
with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...
Phase 3
Seoul, Korea, Republic of and 125 other locations
of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...
Phase 3
Uijeongbu si, Gyeonggi Do, Korea, Republic of and 134 other locations
The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acu...
Phase 1, Phase 2
Seoul, Korea, Republic of and 10 other locations
The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....
Phase 1, Phase 2
Seoul, Korea, Republic of and 35 other locations
Clinical trials
Research sites
Resources
Legal